NEW YORK (GenomeWeb) – Coming under Myriad Genetics' aegis — in a deal worth $225 million upfront and $185 million in milestone payments — Assurex is hoping to push its flagship GeneSight Psychotropic test into new indications, gain greater adoption among primary care docs, and improve the test's payment prospects under a new Medicare law. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.